Wegovy pill form: what's actually available in the UK right now

Is the Wegovy pill genuinely available, or is it still in the pipeline?

It is genuine. The MHRA's approval on 11 June 2026 means oral semaglutide for weight management crossed the legal threshold, the medicine is licensed in the UK and can be prescribed by qualified clinicians through regulated pharmacies. That is different from being freely on shelves. Approval and widespread availability are two separate things, and it is worth being clear-eyed about both.

Private clinics and GPhC-registered online pharmacies were among the first to offer it. NHS access is a different matter entirely. A formal NICE appraisal would need to take place before the tablet could be recommended for NHS prescribing, and that process has not concluded. If you have been searching for when the Wegovy pill would reach the UK, the short answer is: it already has, for private patients.

The quickest check you can do right now: search the GPhC register at pharmacyregulation.org to confirm any pharmacy offering it holds a valid registration. That takes under a minute and tells you whether you are dealing with a regulated dispensing service or not.

What does the dosing schedule actually look like for the tablet?

The escalation runs 1.5 mg, then 4 mg, then 9 mg, arriving at the 25 mg maintenance dose, with at least one month spent at each level before moving up. That titration pattern exists for the same reason the injection uses a gradual increase, letting your system adjust and reducing the likelihood of nausea in the early weeks.

How you take it matters as much as when. The tablet should be the first thing you do in the morning: one tablet, swallowed whole, with up to 120 ml of plain water, before any food, coffee, or other oral medicines. The waiting period is at least 30 minutes. Skipping that window reduces how much semaglutide your body absorbs, which matters because oral bioavailability is already lower than the injection. Your prescriber and the Patient Information Leaflet are the definitive sources for timing and any missed-dose guidance, not forums or this page.

People already stable on the 2.4 mg weekly injection may be able to transition directly to the 25 mg tablet, but that is a clinical decision, not a self-managed switch. If you want a fuller picture of what Wegovy looks like in pill form and how it compares to the injection, that page covers it in detail.

Who does the licence cover, and who falls outside it?

The MHRA approved the Wegovy tablet for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Treatment should sit alongside a reduced-calorie diet and increased physical activity, the tablet is an adjunct to lifestyle change, not a standalone fix.

There are clear exclusions. The medicine is not licensed for anyone under 18. It is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Anyone with a history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or certain gastrointestinal conditions will need a careful prescriber conversation before this is considered suitable.

BMI thresholds under UK guidance are typically set 2.5 kg/m² lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, reflecting well-established differences in cardiometabolic risk at lower body weights. A prescriber looks at the whole picture, not the BMI number alone. You can explore broader weight loss treatment options if you are still working out which route is right for you.

What did the clinical trial evidence show?

The pivotal trial supporting MHRA approval was OASIS 4, a phase 3 study of 307 adults with obesity or overweight plus at least one weight-related condition, conducted over 64 weeks alongside lifestyle support. Average weight loss across all participants was around 13.6% compared with roughly 2.4% on placebo. Among those who stayed fully adherent to treatment throughout, the figure was closer to 17%, a meaningful distinction, since it reflects what the medicine can do under ideal conditions rather than the real-world average across a mixed group.

GI side effects were common: around 74% of tablet users reported nausea, diarrhoea, or similar symptoms at some point, compared with 42% on placebo. Most were mild to moderate and tended to ease as the body adapted. The MHRA's recent communications on semaglutide are worth reading for a full picture of the approved indications this medicine now holds in the UK. For a comparison of oral and injectable options, our page on semaglutide tablets sets out how the different formulations work and what to expect from each. If you are also wondering whether an oral option is currently accessible to you, our page covering whether oral semaglutide is available addresses that question directly. The NHS also publishes patient-level information through its semaglutide medicines guide, which covers what to expect and when to seek medical advice.

If you think the tablet might suit you, a free consultation with a GPhC-registered prescriber is the place to start. At nume, every assessment is read by a real clinician the same day, not processed by software. Start your free consultation to find out whether you are eligible.